Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.

Atovaquone molecular structure

Cancers metabolise a large amount of oxygen in order to create the energy needed to divide, grow and spread rapidly. This results in oxygen-starved, or ‘hypoxic’, environments around tumour cells.

This proves problematic as hypoxic tumours behave more aggressively and are more resistant to most treatments, especially radiotherapy. Radiotherapy relies on oxygen to attack cancer cells, and previous studies have shown that three-times higher doses of radiation are needed to destroy tumours in hypoxic environments, compared to those in oxygen rich environments.

Researchers from the University of Oxford and Oxford University Hospitals Trust have investigated the potential for the commonly used anti-malarial and pneumonia drug Atovaquone to improve lung tumour receptiveness to cancer treatments such as chemotherapy and radiotherapy.

The ATOM study, published today in Clinical Cancer Research, administered Atovaquone to patients with non-small cell lung cancer before the surgical removal of their tumours. Using state-of-the-art scans to measure tumour hypoxia, this study found that tumours had 55% less hypoxic volumes than those who didn’t receive the drug.

Read the full story on the Cancer Research UK Oxford Centre website

Similar stories

Professor Sir Andrew Pollard Awarded the James Spence Medal in 2022

Professor Sir Andrew Pollard, BSc MA MBBS MRCP(UK) FRCPCH PhD DIC FHEA FIDSA FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford, Honorary Consultant Paediatrician at Oxford Children’s Hospital and Vice Master of St Cross College, Oxford.

Department of Paediatrics celebrates 50-year anniversary

After being established in 1972, the Department of Paediatrics' contributions have spanned teaching, innovation, and research. The department also builds upon a longer lineage in Oxford that has impacted child health.

PhD Student of the Year 2022 Winner!

Congratulations to Nuffield Department of Women's & Reproductive Health DPhil student Josephine Agyeman-Duah on being named winner of PhD Student of the Year at the Postgrad Awards 2022.

Ethics at Westminster: A Workshop on Public Values and the Pandemic

At an event organised by the UK Pandemic Ethics Accelerator at the House of Commons on 18 May 2022, parliamentarians, policy makers and academics joined together to discuss how to bring ethical thinking and debate into public policy on pandemic recovery and preparedness, and how to involve the public.

Student Prizes for Biomedical Sciences and Medicine 2021-2022

Congratulations to all our Biomedical Sciences students and Medicine students who have been awarded prizes during the 2021-2022 academic year.